Xu JZ, Garrett ME, Soldano KL, et al. Clinical and metabolomic risk factors associated with rapid renal function decline in sickle cell disease. Am J Hematol. 2018;93(12):1451-1460. doi:10.1002/ajh.25263.

Hermle T, Schneider R, Schapiro D, et al. and Mutations Implicate RAB5 Regulation in Nephrotic Syndrome. J Am Soc Nephrol. 2018;29(8):2123-2138. doi:10.1681/ASN.2017121312.

Christov M, Clark AR, Corbin B, et al. Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities. JCI Insight. 2018;3(4). doi:10.1172/jci.insight.95091.

Kalim S, Wald R, Yan AT, et al. Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles. Clin J Am Soc Nephrol. 2018;13(3):436-444. doi:10.2215/CJN.08790817.

van Zuydam NR, Ahlqvist E, Sandholm N, et al. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes. 2018;67(7):1414-1427. doi:10.2337/db17-0914.

Genovese G, Friedman DJ, Pollak MR. APOL1 variants and kidney disease in people of recent African ancestry. Nat Rev Nephrol. 2013;9(4):240-4. doi:10.1038/nrneph.2013.34.

Williams WW, Pollak MR. Health disparities in kidney disease--emerging data from the human genome. N Engl J Med. 2013;369(23):2260-1. doi:10.1056/NEJMe1312797.

Rhee EP, Feldman HI. Metabolite markers of incident CKD risk. Clin J Am Soc Nephrol. 2014;9(8):1344-6. doi:10.2215/CJN.05910614.

Naik RP, Derebail VK, Grams ME, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA. 2014;312(20):2115-25. doi:10.1001/jama.2014.15063.

Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221-30. doi:10.1038/nm.3814.